ClinicalTrials.gg
RecruitingNCT07557914Updated Nov 10, 2026

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

A Phase 2 interventional study of Epalrestat and Donafenib + Tislelizumab in HCC - Hepatocellular Carcinoma and Diabetes, sponsored by Haibo Shao. Recruiting at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Haibo Shao · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2026, registered Apr 2026).
  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 10, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing donafenib in Carcinoma, Hepatocellular — 9 open to participants now, 9 under way, none of them phase 3. donafenib · Carcinoma, Hepatocellular.

Planned enrollment
8th of 18
32 · median 32
Started
2026
with 1 other
Phase 2
13 of 18
5 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Haibo Shao

Among the 18 studies testing donafenib in Carcinoma, Hepatocellular, this one is the 8th largest by planned enrollment, is one of 2 that started in 2026, is one of 13 in phase 2, and was the 18th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 18 studies testing donafenib in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About donafenib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing donafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.

03

Conditions studied

  • HCC - Hepatocellular Carcinoma
  • Diabetes

Keywords

  • hepatic arterial infusion chemotherapy
  • Donafenib
  • Tislelizumab
  • HCC - Hepatocellular Carcinoma
  • Diabetes
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diabetes mellitus combined with unresectable advanced HCC (BCLC stage C);
  2. Patients who have the need for treatment, prevention and improvement of diabetic neuropathy;
  3. Liver function at grade A or B (≤ 7 points), PS 0-1;
  4. Age 18-80 years old. Confirmed as unrectable HCC through pathological or imaging diagnosis;

Exclusion criteria

Exclusion Criteria:

  1. Severe liver dysfunction: C grade (≥ 8 points) or active hepatic encephalopathy Illness;
  2. Extensive extrahepatic (e.g., lung, bone, or peritoneum metastases);
  3. Severe cardiovascular diseases: Uncontrolled heart failure, recent myocardial infarction;
  4. Renal failure: rate \< 30 mL/min;
  5. Thrombocytopenia (less than 50×10⁹/L) or coagulation dysfunction ( greater than 1.5);
  6. Active infection (such as uncontrolled virus replication with HBV-DNA > 2000 IU/mL);
  7. PS ≥ 2 or extremely poor overall condition;
  8. Diabetic patients with acute ketoacidosis or during the period of severe infection;
  9. Pregnant and lactating women;
  10. Known history of other .
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Epalrestat plus HAIC, donafenib and tislelizumab

    Epalrestat 50mg tid, donafenib 0.2g bid, tislelizumab 200mg per 21days, HAIC (FOLFOX or RALOX) per 21days

    Drug: Epalrestat · Drug: Donafenib + Tislelizumab · Procedure: HAIC

Interventions

  • For the first 6 patients in the safety lead-in period, the starting dose of epalrestat was 50 mg, three times per day. If dose-limiting toxicity (DLT) occurred in the first 6 patients, the dose for the second round of 6 patients in the safety lead-in period would be adjusted to 50 mg, twice per day. If DLT occurred in the second round of 6 patients, the dose for the third round of 6 patients in the safety lead-in period would be adjusted to 50 mg, once per day.

  • DrugDonafenib + Tislelizumab

    Drug pages: DonafenibStudies of DonafenibDonafenib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    donafenib 0.2g BID, tislelizumab 200mg/21days

  • ProcedureHAIC

    Include FOLFOX and RALOX.

    Also known as: hepatic artery infusion chemotherapy

06

What researchers measure

Primary outcomes

  1. 12-month Event-free survival (EFS) Rate

    The proportion of patients who have remained event-free from the start of treatment until the 12-month time point.(Predefined events include: progression of disease, death for any reason, terminate the treatment due to intolerable AEs.)

    Time frame: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.

Secondary outcomes

  1. Event-free survival (EFS)

    Defined as the time from treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs).

    Time frame: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.

  2. Overall survival (OS)

    The OS is defined as the time from the enrollment to death due to any cause.

    Time frame: Up to approximately 2 years

  3. Progression free survival(PFS) (Overall)

    The PFS is defined as the time from the enrollment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first.

    Time frame: From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.

  4. Progression free survival(PFS) of intra-hepatic lesions

    The PFS is defined as the time from the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, whichever occurs first.

    Time frame: From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.

  5. Progression free survival(PFS) of extra-hepatic lesions

    The PFS is defined as the time from the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, whichever occurs first.

    Time frame: From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.

  6. Objective response rate(ORR) per RESCIST 1.1

    The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per RECIST 1.1.

    Time frame: Up to approximately 2 years

  7. ORR per mRECIST

    The ORR is defined as the proportion of patients with a documented CR or PR per mRECIST.

    Time frame: Up to approximately 2 years

  8. PVTT response rate per mRECIST

    The PVTT response rate is defined as the proportion of patients with a documented CR or PR of PVTT. According to the Vp classification: CR: PVTT disappears or the portal vein becomes completely unobstructed. PR: Decrease in VP classification. SD: Without PR and PD. PD: Increase in VP classification.

    Time frame: Up to approximately 2 years

  9. Disease control rate(DCR) per RESCIST 1.1

    The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per RECIST 1.1.

    Time frame: Up to approximately 2 years

  10. DCR per mRECIST

    The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per mRECIST.

    Time frame: Up to approximately 2 years

  11. Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0

    The percentage and degree of patients who experience at least one AE, whether or not considered related to the treatment, according to CTCAE version 5.0.

    Time frame: Up to approximately 2 years

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Consent and privacy: Participants usually only agreed to data use in the original study. Sharing IPD may violate that agreement. And we want to protect our academic credit and avoid misuse of the data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2029, 47 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 47 months is close to that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Oct 2026 → Jan 2026, primary completion Feb 2029 → Dec 2029 and completion Feb 2029 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 30, 2026
StartActual
Jan 21, 2026was Oct 2026
Primary completionEst.
Dec 2029was Feb 2029
CompletionEst.
Dec 2030was Feb 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
3 sites added. The First Hospital of China Medical University is now Active, not recruiting
Show 3 added (3 China)
  • Harbin Medical University Cancer Hospital · Harbin, China
  • Yanbian University Hospital · Yanji, China
  • Liaoning Cancer Hospital · Shenyang, China
Nov 10, 2026
Start date
Oct 2026→Jan 21, 2026 (actual)
Nov 10, 2026
Primary completion
Feb 2029→Dec 2029
Nov 10, 2026
Study completion
Feb 2029→Dec 2030
Nov 10, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The First Hospital of China Medical University · Shenyang, ChinaContact removed h•••@aliyun.com · •••0051Contact removed t•••@sina.com · •••5045
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    3 sites added. The First Hospital of China Medical University is now Active, not recruiting
    Show 3 added (3 China)
    • Harbin Medical University Cancer Hospital · Harbin, China
    • Yanbian University Hospital · Yanji, China
    • Liaoning Cancer Hospital · Shenyang, China
    Start date Oct 2026→Jan 21, 2026 (now actual)
    Primary completion Feb 2029→Dec 2029
    Study completion Feb 2029→Dec 2030
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The First Hospital of China Medical University · Shenyang, ChinaContact removed h•••@aliyun.com · •••0051Contact removed t•••@sina.com · •••5045
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07557914
Lead sponsor
Haibo Shao
Collaborators
First Hospital of China Medical University, Liaoning Cancer Hospital & Institute, The General Hospital of Northern Theater Command, The Affiliated Hospital of Yanbian University, Harbin Medical University Third Affiliated Hospital
Responsible party
Haibo Shao (Professor, MD, PhD, First Hospital of China Medical University) — Sponsor-investigator
First posted
Apr 30, 2026
Start date
Jan 21, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Hongbin Zou
Contact
hongbinzou300@gmail.com
+8618040026871
Haibo Shao
principal investigator · First Hospital of China Medical University
Tao Han
principal investigator · First Hospital of China Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Epalrestat · Donafenib · Tislelizumab

Start the discussion